Creatine HCl and Creatine Ethyl Ester Supplementation in Perimenopausal and Menopausal Women

NCT ID: NCT06660004

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-15

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized controlled double-blind parallel-group interventional trial is to evaluate the effects of of dietary supplementation with creatine HCl and creatine ethyl ester supplementation on cognitive performance, multidimensional fatigue, brain metabolism, and biochemical indices in perimenopausal and menopausal women

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopausal Perimenopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Creatine hcl

One capsule per day of creatine hcl during breakfast

Group Type EXPERIMENTAL

Dietary Supplement: Experimental 1 Creatine HCl

Intervention Type DIETARY_SUPPLEMENT

Creatine hcl

Creatine hcl 2

One capsule during breakfast and one during dinner of creatine hcl

Group Type EXPERIMENTAL

Dietary Supplement: Experimental 2 Creatine HCl

Intervention Type DIETARY_SUPPLEMENT

Creatine hcl

Creatine ethyl ester

One capsule during breakfast and one during dinner of creatine ethyl ester

Group Type EXPERIMENTAL

Dietary Supplement: Experimental 3 Creatine Ethyl ester

Intervention Type DIETARY_SUPPLEMENT

Creatine ethyl ester

Placebo

One capsule per day of inulin during breakfast

Group Type PLACEBO_COMPARATOR

Dietary Supplement: Experimental 4 Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dietary Supplement: Experimental 1 Creatine HCl

Creatine hcl

Intervention Type DIETARY_SUPPLEMENT

Dietary Supplement: Experimental 2 Creatine HCl

Creatine hcl

Intervention Type DIETARY_SUPPLEMENT

Dietary Supplement: Experimental 3 Creatine Ethyl ester

Creatine ethyl ester

Intervention Type DIETARY_SUPPLEMENT

Dietary Supplement: Experimental 4 Placebo

Placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index 18.5 - 29.9 kg/m2
* Free of major chronic diseases or acute disorders (including AD and dementia (MMSE score \> 25 points)
* MENOPAUSAL: no menstrual cycle for consecutive 12 months (with no other obvious causes)
* PERIMENOPAUSAL: Still menstruating (regular or irregular) but have at least one of the following symptoms: (1) hot flashes, (2) sleep disturbances, (3) mood swings, and (4) concentration difficulties
* Given written informed consent

Exclusion Criteria

* History of dietary supplement use 4 weeks before the study commences
* Pregnancy (or planning pregnancy)
* Abnormal values for lab clinical chemistry (\> 2 SD)
* Unwillingness to return for follow-up analysis
* Participation in other clinical trials
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Novi Sad, Faculty of Sport and Physical Education

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sergej Ostojic

Professor, Head of the Applied Bioenergetics Lab

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sergej Ostojic, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Applied BIoenergetics Lab

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

FSPE Applied BIoenergetcis Lab

Novi Sad, Vojvodina, Serbia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Serbia

References

Explore related publications, articles, or registry entries linked to this study.

Ostojic SM, Stea TH, Ellery SJ, Smith-Ryan AE. Association between dietary intake of creatine and female reproductive health: Evidence from NHANES 2017-2020. Food Sci Nutr. 2024 Apr 30;12(7):4893-4898. doi: 10.1002/fsn3.4135. eCollection 2024 Jul.

Reference Type BACKGROUND
PMID: 39055234 (View on PubMed)

Korovljev D, Ostojic J, Panic J, Ranisavljev M, Todorovic N, Nedeljkovic D, Kuzmanovic J, Vranes M, Stajer V, Ostojic SM. The Effects of 8-Week Creatine Hydrochloride and Creatine Ethyl Ester Supplementation on Cognition, Clinical Outcomes, and Brain Creatine Levels in Perimenopausal and Menopausal Women (CONCRET-MENOPA): A Randomized Controlled Trial. J Am Nutr Assoc. 2025 Aug 25:1-12. doi: 10.1080/27697061.2025.2551184. Online ahead of print.

Reference Type DERIVED
PMID: 40854087 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CC-1-24

Identifier Type: -

Identifier Source: org_study_id